Insight

Michael Duruisseaux: Toxicities associated with sequential or combined use of small targeted therapies in lung cancer

Michael Duruisseaux/X

Jul 25, 2024, 15:01

Michael Duruisseaux: Toxicities associated with sequential or combined use of small targeted therapies in lung cancer

Michael Duruisseaux, Thoracic Oncologist at HCL – Hospices Civils de Lyon, shared on X:

“Hot of the press: very pleased to share this team work “Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in lung cancer”.

Led by Thomas Pierret and Dr Desage.”

Source: Michael Duruisseaux/X

Michael Duruisseaux

Authors: Anne-Laure Désage, Michael Duruisseaux, Claire Lafitte, Sophie Bayle-Bleuez, Christos Chouaid. Pierre Fournel, Thomas Pierret

Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature

Anne-Laure Désage cancer Christos Chouaid. Pierre Fournel Claire Lafitte HCL - Hospices Civils de Lyon Lung cancer Michael Duruisseaux OncoDaily Oncology Sophie Bayle-Bleuez Thomas Pierret

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage